Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, USA.
Tissue Eng Part A. 2013 Feb;19(3-4):437-47. doi: 10.1089/ten.TEA.2012.0158. Epub 2012 Oct 19.
Inflammation and angiogenesis are inevitable in vivo responses to biomaterial implants. Continuous progress has been made in biomaterial design to improve tissue interactions with an implant by either reducing inflammation or promoting angiogenesis. However, it has become increasingly clear that the physiological processes of inflammation and angiogenesis are interconnected through various molecular mechanisms. Hence, there is an unmet need for engineering functional tissues by simultaneous activation of pro-angiogenic and anti-inflammatory responses to biomaterial implants. In this work, the modulus and fibrinogen adsorption of porous scaffolds were tuned to meet the requirements (i.e., ~100 kPa and ~10 nm, respectively), for soft tissue regeneration by employing tyrosine-derived combinatorial polymers with polyethylene glycol crosslinkers. Two types of functional peptides (i.e., pro-angiogenic laminin-derived C16 and anti-inflammatory thymosin β4-derived Ac-SDKP) were loaded in porous scaffolds through collagen gel embedding so that peptides were released in a controlled fashion, mimicking degradation of the extracellular matrix. The results from (1) in vitro coculture of human umbilical vein endothelial cells and human blood-derived macrophages and (2) in vivo subcutaneous implantation revealed the directly proportional relationship between angiogenic activities (i.e., tubulogenesis and perfusion capacity) and inflammatory activities (i.e., phagocytosis and F4/80 expression) upon treatment with either type of peptide. Interestingly, cotreatment with both types of peptides upregulated the angiogenic responses, while downregulating the inflammatory responses. Also, anti-inflammatory Ac-SDKP peptides reduced production of pro-inflammatory cytokines (i.e., interleukin [IL]-1β, IL-6, IL-8, and tumor necrosis factor alpha) even when treated in combination with pro-angiogenic C16 peptides. In addition to independent regulation of angiogenesis and inflammation, this study suggests a promising approach to improve soft tissue regeneration (e.g., blood vessel and heart muscle) when inflammatory diseases (e.g., ischemic tissue fibrosis and atherosclerosis) limit the regeneration process.
在生物材料植入物的体内反应中,炎症和血管生成是不可避免的。在生物材料设计方面不断取得进展,通过减少炎症或促进血管生成来改善组织与植入物的相互作用。然而,越来越明显的是,炎症和血管生成的生理过程通过各种分子机制相互关联。因此,需要通过同时激活生物材料植入物的促血管生成和抗炎反应来工程化功能性组织。在这项工作中,通过使用带有聚乙二醇交联剂的酪氨酸衍生组合聚合物,调节多孔支架的模量和纤维蛋白原吸附,以满足软组织再生的要求(即分别约为 100 kPa 和 10nm)。两种类型的功能肽(即促血管生成的层粘连蛋白衍生的 C16 和抗炎的胸腺肽β4衍生的 Ac-SDKP)通过胶原蛋白凝胶嵌入加载到多孔支架中,使得肽以受控的方式释放,模拟细胞外基质的降解。(1)人脐静脉内皮细胞和人血来源的巨噬细胞的体外共培养和(2)皮下植入的体内结果表明,在用任一类肽处理时,血管生成活性(即小管形成和灌注能力)和炎症活性(即吞噬作用和 F4/80 表达)之间存在直接比例关系。有趣的是,两种类型的肽共同处理可上调血管生成反应,同时下调炎症反应。此外,抗炎 Ac-SDKP 肽可减少促炎细胞因子(即白细胞介素 [IL]-1β、IL-6、IL-8 和肿瘤坏死因子α)的产生,即使与促血管生成 C16 肽联合处理也是如此。除了对血管生成和炎症的独立调节外,这项研究还为改善炎症性疾病(如缺血组织纤维化和动脉粥样硬化)限制再生过程时的软组织再生(如血管和心肌)提供了一种很有前途的方法。